Safety of TEG001 in patients with r/r AML/high-risk MDS or r/r MM

Status

Suspended

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517381-42-00

Acronym

NL58686.000.16

Enrollment

Registered

2024-10-14

Start date

2024-10-14

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia (AML), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026